Outcomes from CI administration by CI actually received. (A-D) CAR T-cell recipients vs all alloHCT patients. (E-H) CAR T-cell recipients vs alloHCT patients for whom alloHCT was intended after failure of ≥2L. (A,E) OS. (B,F) PFS. (C,G) Incidence of relapse/progression. (D,H) NRM. Note that all CAR T-cell applications were intended after failure of ≥2L.